Takeda Pharmaceutical
United States
About Takeda Pharmaceutical
1311 articles with Takeda Pharmaceutical
-
Takeda Announces Publication of Data from SOLSTICE, a Pivotal Phase 3 Trial for LIVTENCITY™ (Maribavir) in Post-Transplant Recipients With Cytomegalovirus (CMV) Infection (Refractory, With or Without Resistance)
12/8/2021
Takeda Pharmaceutical Company today announced that the data from the pivotal Phase 3 SOLSTICE clinical trial of LIVTENCITY were published in the journal of Clinical Infectious Diseases (CID).
-
Takeda Unveils New Research to Advance Patient Care in Hematology and Oncology at 63rd American Society of Hematology (ASH) Annual Meeting
12/7/2021
Takeda Unveils New Research to Advance Patient Care in Hematology and Oncology at 63rd American Society of Hematology (ASH) Annual Meeting.
-
Takeda Announces U.S. Corporate Social Responsibility (CSR) Program Aimed to Help Reduce Social Disparities
11/30/2021
Takeda Pharmaceutical Company Limited announced that it is enhancing its Corporate Social Responsibility Program in the U.S., making an initial commitment of $20 million its first year supporting organizations in the U.S. to help improve equity among underrepresented communities in the areas of health, education, the environment and access to nutrition/food.
-
The FDA approved Takeda’s Livtencity (maribavir) for adults and children 12 years or older with post-transplant cytomegalovirus (CMV) infection.
-
Takeda’s LIVTENCITYTM (maribavir) Approved by U.S. FDA as the First and Only Treatment for People Ages 12 and Older with Post-Transplant Cytomegalovirus (CMV), Refractory (With or Without Genotypic Resistance) to Conventional Antiviral Therapies
11/23/2021
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) has approved LIVTENCITY™.
-
FDA Action Alert: Takeda, Aadi and Fennec
11/22/2021
The U.S. Food and Drug Administration has a few PDUFA dates for the Thanksgiving Holiday week. Here’s a look. -
Canadian Blood Services Awards Takeda Canada Three-Year Tender for Hemophilia treatment ADYNOVATE®
11/17/2021
Takeda Canada is pleased to announce that Canadian Blood Services has awarded a three-year tender for ADYNOVATE®i [Antihemophilic Factor PEGgylated] as part of its request for proposal for recombinant Factor VIII Standard Half-Life process as part of its formulary product mix.
-
HemoShear Therapeutics Identifies Second Novel Target to Treat NASH Through Successful Collaboration with Takeda
11/16/2021
HemoShear Therapeutics, Inc. announced today that a second target identified utilizing the company's REVEAL-Tx ™ human disease modeling platform has been selected by Takeda Pharmaceutical Company Limited
-
Kindness. Respect. Innovation. Only one of those words typically features in biotech mission statements, but at Ikena Oncology, all three are important – and have been from day one.
-
Takeda Recommends Common-sense Policy Reforms Designed to Reduce Time to Diagnosis, Improve Access to Care for Patients with Rare Disease
11/4/2021
As part of its commitment to reducing burdens facing the rare disease community, Takeda Pharmaceutical Company Limited announced three priority policy reforms and solutions designed to address significant barriers to care for patients managing rare diseases and genetic conditions as part of a new report, “Reducing Time to Diagnosis for People Living with Rare Diseases: A Conversation on U.S. Policy Opportunities.”
-
Takeda Applied for Selection of “Prime Market”, Filed Corporate Governance Report With Tokyo Stock Exchange (TSE) in Line With Revised Corporate Governance Code and Published Corporate Governance Related Documents on its Website
11/1/2021
Takeda Pharmaceutical Company Limited applied for selection of the “Prime Market” segment of the Tokyo Stock Exchange, Inc. as its listing market as determined at the Board of Directors Meeting held on September 29 and 30, 2021.
-
Although the literature suggests this condition may affect 200 people globally, Williams and his team think the numbers are higher.
-
Takeda Delivers Strong H1 FY2021 Results; Further Growth Momentum Expected Through Fiscal Year-End Driven by 14 Global Brands
10/28/2021
Takeda Pharmaceutical Company Limited announced financial results for the first half of fiscal year 2021.
-
Takeda Announces Acquisition of Own Shares - Oct 28, 2021
10/28/2021
Takeda Pharmaceutical Company Limited announced that its Board of Directors resolved to engage in the acquisition of its own shares pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act of Japan, as detailed below.
-
Collaboration is key to faster breakthroughs. The NIH, FDA, and 15 private organizations have announced they are joining forces for the sake of the 30 million Americans suffering from a rare disease.
-
The deal was struck one month after GammaDelta dosed its first patient in a Phase I acute myeloid leukemia (AML) trial.
-
Calithera Biosciences is expanding its oncology portfolio with the addition of two clinical-stage compounds from Takeda Pharmaceuticals.
-
Wave Life Sciences and Takeda Amend CNS Collaboration
10/18/2021
Amendment to ongoing collaboration allows Wave to advance or partner CNS programs, including those using ADAR editing Takeda option to co-develop and co-commercialize late-stage CNS programs, including clinical programs WVE-004 and WVE-003, remains unchanged
-
Calithera Expands Oncology Pipeline with Acquisition of Two Clinical-Stage Assets from Takeda Pharmaceuticals
10/18/2021
Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced an agreement with Takeda Pharmaceutical Company Limited (“Takeda”) to acquire two clinical-stage compounds, both of which have demonstrated single-agent clinical activity with the greatest potential in biomarker-defined cancer-patient populations.
-
Immusoft and Takeda Collaborate to Discover and Develop Cell Therapies for Rare Neurometabolic Disorders
10/13/2021
Immusoft announced today that it has signed a research collaboration and license option agreement with Takeda Pharmaceutical Company Limited ("Takeda") to discover, develop and commercialize transformative cell therapies in rare inherited metabolic disorders with central nervous system (CNS)